Tempest Therapeutics Inc. has announced management changes as part of a plan to extend its capital resources and explore strategic alternatives. Effective June 5, 2025, CEO Stephen Brady, EVP and Chief Medical Officer Samuel Whiting, and CFO Nicholas Maestas have transitioned to consulting roles with the company. Each will continue to serve in their respective executive capacities under one-year consulting agreements. The transitions come without any disagreements between the executives and the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.